NCT00420186 - A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

Cancer (Solid Tumors)

Interventions

DRUG

BMS-690514

Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

17033

Penn State Milton S. Hershey Medical Center, Hershey

K1H 8L6

Local Institution, Ottawa

M20 4BX

Local Institution, Manchester